Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
Compass has boosted its IPO financing by roughly 20% AND increased the unit price -- signalling strong interest in the psychedelic space.
Newest IPO hits September 21- MCUR
Compass Pathways has upsized its IPO financing to $127.5 million, at an offering price of $17.00 per American Depositiry Share (ADS).
A $225 billion treatment market is badly in need of new therapies. Here is the roadmap for investors to capitalize on this opportunity.
Functional mushrooms are a large-and-growing health supplements market with synergies to psychedelics operations.
Champignon Brands continues to work with the BC Secutiries Commission to complete its disclosure review.
Mydecine is planning to spin out its U.S. legacy cannabis assets.
Compass Pathways has set the terms for its IPO, targeting a valuation at or about $544.1 million.
Spravato has not been the "game-changer" for treating depression that it was touted as being. The market remains wide open for psilocybin (and other psychedelics).
ATAI Life Sciences is looking more and more like the driving force in the psychedelic drug industry.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now